DOP2015000132A - Moduladores selectivos del receptor de andrógenos novedosos - Google Patents
Moduladores selectivos del receptor de andrógenos novedososInfo
- Publication number
- DOP2015000132A DOP2015000132A DO2015000132A DO2015000132A DOP2015000132A DO P2015000132 A DOP2015000132 A DO P2015000132A DO 2015000132 A DO2015000132 A DO 2015000132A DO 2015000132 A DO2015000132 A DO 2015000132A DO P2015000132 A DOP2015000132 A DO P2015000132A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- branched chain
- chain alkyl
- straight
- hydrogen
- independently hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UN COMPUESTO DE LA FÓRMULA 1, 2 Ó 3: EN DONDE A ES N O CR0, DONDE R0 ES HIDRÓGENO, ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ETC., Z ES CRE, O, N, DONDE RE ES HIDRÓGENO, ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ETC.; R1 ES HIDRÓGENO, ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ETC.; R2 SON INDEPENDIENTEMENTE HIDRÓGENO O ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6; R3 Y R4 SON INDEPENDIENTEMENTE HIDRÓGENO, ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ETC.; R5 Y R6 SON INDEPENDIENTEMENTE HIDRÓGENO O ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ETC.; R8 ES HIDRÓGENO, ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ETC.; R9 Y R10 SON INDEPENDIENTEMENTE HIDRÓGENO O ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ETC.; Q ES CO, (CH2)Q, (CHRS)Q, O (CRSRT)Q, DONDE RS Y RT SON INDEPENDIENTEMENTE ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ARILO, ALQUILARILO, HETEROARILO O ALQUILHETEROARILO; EN DONDE Q ES 0, 1, 2, O 3; Y, DONDE N ES 0, 1, 2, 3, 4 Ó 5; O, UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LOS MISMOS, PARA COMPOSICIONES QUE CONTIENEN TALES COMPUESTOS; Y PARA LOS USOS DE TALES COMPUESTOS EN EL TRATAMIENTO DE DIVERSAS ENFERMEDADES, PARTICULARMENTE, AQUELLAS AFECTADAS O MEDIADAS POR EL RECEPTOR DE ANDRÓGENOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261732617P | 2012-12-03 | 2012-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2015000132A true DOP2015000132A (es) | 2015-12-31 |
Family
ID=49955433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2015000132A DOP2015000132A (es) | 2012-12-03 | 2015-06-03 | Moduladores selectivos del receptor de andrógenos novedosos |
Country Status (34)
Country | Link |
---|---|
US (1) | US9328104B2 (es) |
EP (1) | EP2925725B1 (es) |
JP (1) | JP6039100B2 (es) |
KR (1) | KR101745225B1 (es) |
CN (1) | CN104854093B (es) |
AP (1) | AP2015008444A0 (es) |
AR (1) | AR093697A1 (es) |
AU (1) | AU2013353723B2 (es) |
BR (1) | BR112015011897B1 (es) |
CA (1) | CA2891234C (es) |
CL (1) | CL2015001495A1 (es) |
CO (1) | CO7400864A2 (es) |
CR (1) | CR20150290A (es) |
CU (1) | CU20150054A7 (es) |
DK (1) | DK2925725T3 (es) |
DO (1) | DOP2015000132A (es) |
EA (1) | EA026562B1 (es) |
ES (1) | ES2609596T3 (es) |
HK (1) | HK1209744A1 (es) |
IL (1) | IL239076B (es) |
MA (1) | MA38114A1 (es) |
MD (1) | MD20150049A2 (es) |
MX (1) | MX368898B (es) |
MY (1) | MY176727A (es) |
NZ (1) | NZ707752A (es) |
PE (1) | PE20151158A1 (es) |
PH (1) | PH12015501215B1 (es) |
SG (1) | SG11201503580WA (es) |
TN (1) | TN2015000237A1 (es) |
TW (1) | TWI518083B (es) |
UA (1) | UA110766C2 (es) |
UY (1) | UY35158A (es) |
WO (1) | WO2014087298A1 (es) |
ZA (1) | ZA201503517B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015260906B2 (en) | 2014-05-15 | 2017-08-31 | Pfizer Inc. | Crystalline form of 6-((4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl)isoquinoline-1-carbonitrile |
WO2015181676A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
CN107573270B (zh) * | 2017-09-29 | 2019-11-29 | 河南师范大学 | 一种α-甲酰基吡咯烷类化合物的合成方法 |
CN110372628B (zh) * | 2019-07-09 | 2021-04-02 | 武汉大学 | 内磺酰胺类化合物及其制备方法 |
WO2021050913A1 (en) * | 2019-09-12 | 2021-03-18 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
WO2023275715A1 (en) * | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE638650C (de) | 1934-06-08 | 1936-11-20 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung von 3, 4-Dioxyphenylmonoalkylaminobutanolen-1 |
US2482055A (en) | 1948-02-11 | 1949-09-13 | American Cyanamid Co | Aureomycin and preparation of same |
US2715141A (en) | 1952-03-27 | 1955-08-09 | Delmar Chem | Optically active isopropyl arterenol |
US3377364A (en) | 1957-09-23 | 1968-04-09 | Upjohn Co | 6-methyl-17alpha-hydroxyprogesterone, the lower fatty acid 17-acylates and methods for producing the same |
US3332940A (en) | 1959-08-28 | 1967-07-25 | British Drug Houses Ltd | Process for the preparation of 17alpha-acyloxy-6-methyl-16-methylene-4, 6-pregnadiene-3, 20-diones and intermediates obtained therefrom |
US3359287A (en) | 1959-11-16 | 1967-12-19 | Upjohn Co | 16-methylene-17alpha-hydroxy progesterones and derivatives thereof |
DE1275069B (de) | 1960-02-15 | 1968-08-14 | Boehringer Sohn Ingelheim | 1-(3', 5'-Dihydroxyphenyl)-1-hydroxy-2-isopropylaminoalkane und Verfahren zu ihrer Herstellung |
DE1158966B (de) | 1961-04-29 | 1963-12-12 | Schering Ag | Verfahren zur Herstellung von 6-Chlor-1, 2ª-methylen-í¸-17ª-hydroxyprogesteronestern |
NL130078C (es) | 1963-06-11 | |||
US3239345A (en) | 1965-02-15 | 1966-03-08 | Estrogenic compounds and animal growth promoters | |
DE1618005A1 (de) | 1966-09-22 | 1971-09-09 | Thomae Gmbh Dr K | Verfahren zur Herstellung von neuen Amino-dihalogen-phenyl-aethylaminen |
GB1200886A (en) | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
US4138581A (en) | 1969-04-01 | 1979-02-06 | Sterling Drugs Inc. | 3(Hydroxy or hydroxymethyl)-4(hydroxy)-α-(aminomethyl)benzyl alcohols |
US3705169A (en) | 1970-11-05 | 1972-12-05 | Smith Kline French Lab | Hydroxyphenyl-2-piperidinylcarbinols |
US3763232A (en) | 1971-01-11 | 1973-10-02 | Smith Kline French Lab | Alpha-aminoalkyl-4-hydroxy-3-ureidobenzyl alcohols |
US3700681A (en) | 1971-02-16 | 1972-10-24 | Pfizer | 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines |
BE788737A (fr) | 1971-09-13 | 1973-01-02 | Hokuriku Pharmaceutical | Procede de preparation de derives de l'alcool o-chlorobenzylique |
BE789629A (fr) | 1971-10-05 | 1973-04-03 | Sandoz Sa | Nouveaux derives de la pleuromutiline, leur preparation et leurapplication en therapeutique |
US3919290A (en) | 1972-10-03 | 1975-11-11 | Sandoz Ltd | Substituted 14-desoxy-mutilins |
US3839557A (en) | 1972-01-24 | 1974-10-01 | Lilly Co Eli | Antibiotics monensin and a204 for improving ruminant feed efficiency |
US3939265A (en) | 1972-05-10 | 1976-02-17 | Jean Andre Grandadam | Novel zootechnical compositions |
US4119710A (en) | 1972-12-18 | 1978-10-10 | Boehringer Ingelheim Gmbh | Bronchospasmolytic 1-(p-amino-phenyl)-2-amino-ethanols-(1) and salts |
US4026897A (en) | 1974-01-31 | 1977-05-31 | Otsuka Pharmaceutical Company | 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives |
US4048268A (en) | 1975-02-19 | 1977-09-13 | Eli Lilly And Company | Stabilization method |
US3987194A (en) | 1975-05-12 | 1976-10-19 | E. R. Squibb & Sons, Inc. | Use of pleuromutilin derivatives for the treatment of swine dysentery |
US3995027A (en) | 1975-06-04 | 1976-11-30 | Eli Lilly And Company | Anti-viral method in animals |
FR2388560A1 (fr) | 1977-04-27 | 1978-11-24 | Roussel Uclaf | Nouvelles compositions zootechniques renfermant d'une part le zeranol et d'autre part un steroide 4,9,11 trienique |
US4154748A (en) | 1978-01-20 | 1979-05-15 | The Upjohn Company | Phosphate catalyzed acylation of steroidal tertiary alcohols |
US4283388A (en) | 1979-12-26 | 1981-08-11 | Eli Lilly And Company | Method for treating colibacillosis in pigs with tylosin apramycin compositions |
DE3163871D1 (en) | 1980-07-09 | 1984-07-05 | Draco Ab | 1-(dihydroxyphenyl)-2-amino-ethanol derivatives; preparation, compositions and intermediates |
US5643967A (en) | 1983-01-31 | 1997-07-01 | Eli Lilly And Company | Growth promotion |
IE60964B1 (en) | 1986-12-11 | 1994-09-07 | Roussel Uclaf | Zootechnical compositions containing a beta-adrenergic |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
DE4014252A1 (de) | 1990-05-04 | 1991-11-07 | Boehringer Ingelheim Vetmed | Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer |
GB9107196D0 (en) | 1991-04-05 | 1991-05-22 | Sandoz Ag | Improvements in or relating to organic compounds |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
AUPO776897A0 (en) | 1997-07-09 | 1997-07-31 | Csl Limited | A method of achieving production gains in livestock and agents useful for same |
JP4426792B2 (ja) * | 2002-08-12 | 2010-03-03 | 武田薬品工業株式会社 | 縮合ベンゼン誘導体および用途 |
JP2007505164A (ja) * | 2003-06-10 | 2007-03-08 | スミスクライン ビーチャム コーポレーション | アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての1−アミノナフタレン類 |
JP4709759B2 (ja) * | 2003-08-22 | 2011-06-22 | リガンド・ファーマシューティカルズ・インコーポレイテッド | アンドロゲン受容体モジュレーター化合物としての6−シクロアミノ−2−キノリノン誘導体 |
AU2005247405A1 (en) * | 2004-05-17 | 2005-12-08 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
US8354446B2 (en) * | 2007-12-21 | 2013-01-15 | Ligand Pharmaceuticals Incorporated | Selective androgen receptor modulators (SARMs) and uses thereof |
BRPI0907844B8 (pt) * | 2008-02-22 | 2021-05-25 | Radius Health Inc | compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos |
-
2013
- 2013-11-25 DK DK13820949.9T patent/DK2925725T3/en active
- 2013-11-25 MX MX2015006987A patent/MX368898B/es active IP Right Grant
- 2013-11-25 PE PE2015000720A patent/PE20151158A1/es not_active Application Discontinuation
- 2013-11-25 CA CA2891234A patent/CA2891234C/en active Active
- 2013-11-25 AU AU2013353723A patent/AU2013353723B2/en not_active Ceased
- 2013-11-25 JP JP2015544586A patent/JP6039100B2/ja not_active Expired - Fee Related
- 2013-11-25 KR KR1020157017712A patent/KR101745225B1/ko active IP Right Grant
- 2013-11-25 EA EA201590757A patent/EA026562B1/ru not_active IP Right Cessation
- 2013-11-25 CN CN201380062913.XA patent/CN104854093B/zh not_active Expired - Fee Related
- 2013-11-25 MY MYPI2015701459A patent/MY176727A/en unknown
- 2013-11-25 BR BR112015011897-6A patent/BR112015011897B1/pt not_active IP Right Cessation
- 2013-11-25 EP EP13820949.9A patent/EP2925725B1/en active Active
- 2013-11-25 MA MA38114A patent/MA38114A1/fr unknown
- 2013-11-25 NZ NZ707752A patent/NZ707752A/en not_active IP Right Cessation
- 2013-11-25 AP AP2015008444A patent/AP2015008444A0/xx unknown
- 2013-11-25 ES ES13820949.9T patent/ES2609596T3/es active Active
- 2013-11-25 UA UAA201504472A patent/UA110766C2/uk unknown
- 2013-11-25 SG SG11201503580WA patent/SG11201503580WA/en unknown
- 2013-11-25 MD MDA20150049A patent/MD20150049A2/ro not_active Application Discontinuation
- 2013-11-25 WO PCT/IB2013/060381 patent/WO2014087298A1/en active Application Filing
- 2013-11-28 TW TW102143554A patent/TWI518083B/zh not_active IP Right Cessation
- 2013-11-29 UY UY0001035158A patent/UY35158A/es not_active Application Discontinuation
- 2013-12-02 US US14/093,812 patent/US9328104B2/en active Active
- 2013-12-02 AR ARP130104447A patent/AR093697A1/es unknown
-
2015
- 2015-05-19 ZA ZA2015/03517A patent/ZA201503517B/en unknown
- 2015-05-28 IL IL239076A patent/IL239076B/en active IP Right Grant
- 2015-05-29 PH PH12015501215A patent/PH12015501215B1/en unknown
- 2015-05-29 CU CUP2015000054A patent/CU20150054A7/es unknown
- 2015-05-29 CR CR20150290A patent/CR20150290A/es unknown
- 2015-06-01 TN TNP2015000237A patent/TN2015000237A1/fr unknown
- 2015-06-02 CO CO15126416A patent/CO7400864A2/es unknown
- 2015-06-03 DO DO2015000132A patent/DOP2015000132A/es unknown
- 2015-06-03 CL CL2015001495A patent/CL2015001495A1/es unknown
- 2015-10-28 HK HK15110628.2A patent/HK1209744A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2015000132A (es) | Moduladores selectivos del receptor de andrógenos novedosos | |
PH12017501192B1 (en) | Certain amino-pyridazines, compositions thereof, and methods of their use | |
PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
CR20140042A (es) | Indazoles | |
UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
MX2016015467A (es) | Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos. | |
MY186165A (en) | New bicyclic dihydroquinoline-2-one derivatives | |
PE20150623A1 (es) | Moduladores de la ruta del complemento y usos de los mismos | |
MX2013012211A (es) | Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato. | |
AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
MX2015001099A (es) | Nuevos derivados biciclicos de piridina. | |
DOP2014000178A (es) | Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2 | |
CY1119296T1 (el) | Ενωση δικαρβοξυλικου οξεος | |
ECSP13012366A (es) | Procedimiento de preparación de la sal de l-arginina de perindoprilo | |
PH12014502285A1 (en) | Anti-malarial agents | |
CR20160030A (es) | Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
CR20130476A (es) | Derivados de pirazolidin-3-ona | |
ECSP13012735A (es) | Nuevo procedimiento de síntesis de la agomelatina | |
ECSP14011505A (es) | Derivados de bencil sulfonamida útiles como inhibidores de mogat-2 | |
UY35743A (es) | Procedimiento de síntesis para la preparación de analogos c1-ceto macrociclicos de halicondrina b e intermediarios útiles en el mismo | |
CO6731102A2 (es) | Nuevo procedimiento de síntesis de la agomelatina |